CytomX Therapeutics, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Merck for CytomX's first-in-human Phase 1 clinical trial assessing the clinical activity of CX-801, a dually-masked interferon-alpha2b cytokine in combination with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.89 USD | -5.50% | -4.55% | +21.94% |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
131.2 USD | +0.24% | +0.87% | 332B | ||
1.89 USD | -5.50% | -4.55% | 147M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+21.94% | 147M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.87B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- CTMX Stock
- News CytomX Therapeutics, Inc.
- CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)